ArticleInvestigational new drugs2023

Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.

Markus Haas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.